^
    Back
    Association details:
    Biomarker:EGFR exon 20 insertion
    Cancer:Non Small Cell Lung Cancer
    Regimen:ABCP
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Lung Cancer
    Title:

    NSCLC with uncommon EGFR mutations treated with atezolizumab plus bevacizumab and chemotherapy

    Published date:
    11/13/2022
    Excerpt:
    Sixteen stage IV NSCLC patients with uncommon EGFR mutations from 9 different German centers were treated in first or further line with Atezolizumab, Bevacizumab, Carboplatin and (nab-)Paclitaxel (ABCP)….Median PFS was 13.6 months for both the entire cohort and for Exon 20 insertions.
    DOI:
    https://doi.org/10.1016/j.lungcan.2022.11.006